Vestal Point Capital, LP Fate Therapeutics Inc Transaction History
Vestal Point Capital, LP
- $1.9 Trillion
- Q2 2025
A detailed history of Vestal Point Capital, LP transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Vestal Point Capital, LP holds 2,515,000 shares of FATE stock, worth $2.41 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
2,515,000
Previous 2,515,850
0.03%
Holding current value
$2.41 Million
Previous $1.99 Billion
41.71%
% of portfolio
0.15%
Previous 0.14%
Shares
7 transactions
Others Institutions Holding FATE
# of Institutions
150Shares Held
83.4MCall Options Held
179KPut Options Held
13.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$12.4 Million1.75% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$9.71 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$8.42 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.54MShares$4.36 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY3.4MShares$3.26 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $93.1M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...